{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:17:20Z","timestamp":1790273840764,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201779","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:40:54Z","timestamp":1781160054000},"page":"201779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intra-CNS AAV9-GBA1 delivery yields species and route of administration differences in safety and transgene expression"],"prefix":"10.1016","volume":"34","author":[{"given":"Ana Claudia","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Grubor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1208-6046","authenticated-orcid":false,"given":"Lee","family":"Koetzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Bourque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay-Ellen","family":"Chicoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Clarner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"De Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odete R.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merilla","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali V.P.","family":"Nadella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sebalusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weike","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Trapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Plowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Fikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren D.","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghae","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Glajch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201779_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omta.2026.201779_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.omta.2026.201779_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.tins.2021.12.004","article-title":"Lysosomal dysfunction in neurodegeneration: emerging concepts and methods","volume":"45","author":"Udayar","year":"2022","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.omta.2026.201779_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1064924","article-title":"Gene therapy for lysosomal storage diseases: Current clinical trial prospects","volume":"14","author":"Kido","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.omta.2026.201779_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/biom11040611","article-title":"Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development","volume":"11","author":"Massaro","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.omta.2026.201779_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101593","article-title":"Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates","volume":"33","author":"Okai","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2016.24","article-title":"Axonal transport of AAV9 in nonhuman primate brain","volume":"23","author":"Green","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib12","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201779_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104856","article-title":"Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review","volume":"141","author":"Gaubert","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.omta.2026.201779_bib14","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049192","article-title":"The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models","volume":"15","author":"Polinski","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omta.2026.201779_bib15","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/mds.28815","article-title":"Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity","volume":"36","author":"Ysselstein","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omta.2026.201779_bib16","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ymthe.2018.07.008","article-title":"Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS","volume":"26","author":"Naidoo","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201779_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101371","article-title":"Comparative assessment of the transduction efficiency and safety associated with the delivery of AAV9-GFP vector via lumbar puncture to cynomolgus macaques with and without anti-AAV9 pre-existing antibodies","volume":"32","author":"Guibinga","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/01926233221101309","article-title":"Intrathecal sc-AAV9-CB-GFP: Systemic Distribution Predominates Following Single-Dose Administration in Cynomolgus Macaques","volume":"50","author":"Meseck","year":"2022","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omta.2026.201779_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101536","article-title":"Early postnatal expression mitigates immune responses to Cas9 in the murine central nervous system","volume":"33","author":"Duba-Kiss","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/gt.2014.121","article-title":"Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats","volume":"22","author":"Hordeaux","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib21","doi-asserted-by":"crossref","first-page":"e67680","DOI":"10.1371\/journal.pone.0067680","article-title":"Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain","volume":"8","author":"Chakrabarty","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201779_bib22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/acn3.51165","article-title":"Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations","volume":"7","author":"Hinderer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omta.2026.201779_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/hum.2013.005","article-title":"Strong Cortical and Spinal Cord Transduction After AAV7 and AAV9 Delivery into the Cerebrospinal Fluid of Nonhuman Primates","volume":"24","author":"Samaranch","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","article-title":"Kinetics and MR-Based Monitoring of AAV9 Vector Delivery into Cerebrospinal Fluid of Nonhuman Primates","volume":"13","author":"Ohno","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib26","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","article-title":"Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results","volume":"30","author":"Sevigny","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201779_bib27","doi-asserted-by":"crossref","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201779_bib28","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo","volume":"10","author":"Mccarty","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.omtm.2022.01.013","article-title":"Characterization of AAV-mediated dorsal root ganglionopathy","volume":"24","author":"Buss","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201779_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201779_bib33","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2019.012","article-title":"Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys","volume":"30","author":"Hordeaux","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL\/6J Mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201779_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.omtm.2022.12.012","article-title":"Neurofilament light chain and dorsal root ganglia injury after adeno-associated virus 9 gene therapy in nonhuman primates","volume":"28","author":"Johnson","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.omta.2026.201779_bib38","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/ijms25021050","article-title":"Delivery of Adeno-Associated Virus Vectors to the Central Nervous System for Correction of Single Gene Disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201779_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac6191","article-title":"AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease","volume":"7","author":"Katz","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201779_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JPD-212739","article-title":"Gene Therapy for Parkinson\u2019s Disease Associated with GBA1 Mutations","volume":"11","author":"Abeliovich","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.omta.2026.201779_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101602","article-title":"Impact of pre-existing immunity on safety and biodistribution of a single AAV9 vectorintrathecal injection in cynomolgus monkeys","volume":"33","author":"Vono","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101643","article-title":"Inhibition of immune response reduces pathology in dorsal root ganglia and peripheral nerves in cynomolgus macaques following AAV gene therapy","volume":"33","author":"Grubor","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/hum.2006.17.291","article-title":"Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain","volume":"17","author":"Hadaczek","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nbd.2011.10.004","article-title":"Glial-derived neurotrophic factor gene transfer for Parkinson\u2019s disease: Anterograde distribution of AAV2 vectors in the primate brain","volume":"48","author":"Kells","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omta.2026.201779_bib45","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1073\/pnas.0810682106","article-title":"Efficient gene therapy-based method for the delivery of therapeutics to primate cortex","volume":"106","author":"Kells","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201779_bib46","doi-asserted-by":"crossref","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene Therapy for Aromatic l-Amino Acid Decarboxylase Deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201779_bib47","first-page":"1427","article-title":"Eladocagene Exuparvovec: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.omta.2026.201779_bib48","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201779_bib49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib50","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/hum.2016.109","article-title":"Direct Intracranial Injection of AAVrh8 Encoding Monkey \u03b2-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain. Hum","volume":"28","author":"Golebiowski","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates","volume":"26","author":"Zerah","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omta.2026.201779_bib52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/hum.2020.269","article-title":"Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy","volume":"32","author":"Rosenberg","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201779_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51984-2","article-title":"Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies","volume":"9","author":"Alexaki","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201779_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/10915818211073047","article-title":"Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies","volume":"41","author":"Kale","year":"2022","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.omta.2026.201779_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000323544","article-title":"Novel Platform for MRI-Guided Convection-Enhanced Delivery of Therapeutics: Preclinical Validation in Nonhuman Primate Brain. Stereotact","volume":"89","author":"Richardson","year":"2011","journal-title":"Funct. Neurosurg."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:13:52Z","timestamp":1789053232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X2600114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X2600114X"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201779","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intra-CNS AAV9-GBA1 delivery yields species and route of administration differences in safety and transgene expression","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201779"}}